Last reviewed · How we verify
Placebo (matched to IVA)
Placebo is an inert control substance with no active pharmacological mechanism.
Placebo is an inert control substance with no active pharmacological mechanism. Used for Control comparator in phase 3 clinical trial for IVA (specific indication unknown).
At a glance
| Generic name | Placebo (matched to IVA) |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a comparator arm in clinical trials to establish the efficacy of the active investigational drug (IVA) by controlling for non-specific effects, natural disease progression, and patient expectations. It contains no active pharmaceutical ingredient and produces therapeutic effects only through psychological mechanisms such as expectation and conditioning.
Approved indications
- Control comparator in phase 3 clinical trial for IVA (specific indication unknown)
Common side effects
Key clinical trials
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) (PHASE3)
- Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion (PHASE2)
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) (PHASE3)
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation (PHASE3)
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation (PHASE3)
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (matched to IVA) CI brief — competitive landscape report
- Placebo (matched to IVA) updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI